Jessica Slaba
Nurse Practitioner · Sioux Falls, SDNPI 1770190993
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,982 of the $40,945 with a category attached, or 75.7%. Geron Corporation accounts for 75.0% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $36,811, more than ten times the $16 reported in 2022. Among nurse practitioner clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $372.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Geron Corporation$31K
- E.r. Squibb & Sons, L.L.C.$9K
- Bristol Myers Squibb$391
- Legend Biotech USA Inc.$108
- AbbVie$84
- Novartis$79
- plus $563 from 16 others
What the payments were for
- Consulting fees$1,6354%
- Speaking & faculty fees$30,98276%
- Travel & lodging$5,88714%
- Food & beverage$2,4416%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Geron Corporation | 41 | $30,716 |
| E.r. Squibb & Sons, L.L.C. | 23 | $9,004 |
| Bristol Myers Squibb | 6 | $391 |
| Legend Biotech USA Inc. | 4 | $108 |
| AbbVie | 3 | $84 |
| Novartis | 4 | $79 |
| AstraZeneca | 5 | $77 |
| Johnson & Johnson | 3 | $71 |
| Beigene USA, Inc. | 3 | $60 |
| Rigel Pharmaceuticals, Inc. | 2 | $39 |
| Genentech USA, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Sanofi | 2 | $38 |
| ADC Therapeutics America, Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Genmab U.S., Inc. | 1 | $26 |
| Incyte Corporation | 1 | $24 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Teleflex LLC | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,945 in reported general payments places this provider in the 95th percentile of 504 nurse practitioner providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 148 | $2,441,893 |
| ImbruvicaIbrutinib | 47 | $849,270 |
| CalquenceAcalabrutinib Maleate | 39 | $540,926 |
| PomalystPomalidomide | 25 | $401,992 |
| BrukinsaZanubrutinib | 25 | $361,470 |
| VenclextaVenetoclax | 38 | $310,051 |
| JakafiRuxolitinib Phosphate | 24 | $282,083 |
| RydaptMidostaurin | 12 | $252,524 |
| JaypircaPirtobrutinib | 11 | $227,997 |
| PromactaEltrombopag Olamine | 17 | $188,372 |
| EliquisApixaban | 16 | $13,620 |
| XareltoRivaroxaban | 15 | $11,253 |
| Imatinib Mesylate | 21 | $2,745 |
| ValacyclovirValacyclovir Hcl | 64 | $2,583 |
| Hydroxyurea | 105 | $1,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $391 | $2,441,893148 claims |
| AstraZenecaCalquence | $77 | $540,92639 claims |
| NovartisRydapt, Promacta | $79 | $440,89629 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $9,004 | $401,99225 claims |
| Beigene USA, Inc.Brukinsa | $60 | $361,47025 claims |
| AbbVieVenclexta | $84 | $310,05138 claims |
| Incyte CorporationJakafi | $24 | $282,08324 claims |
| Johnson & JohnsonXarelto | $71 | $11,25315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 nurse practitioner providers in South Dakota.
Other nurse practitioner in Sioux Falls
- Jamie BuschSioux Falls$60K
- Christopher NelsonSioux Falls$35K
- Katherine EricsonSioux Falls$13K
- Gabrielle PriceSioux Falls$5K
- Jacqueline KelleySioux Falls$5K
- Jessica YoshinoSioux Falls$5K
- Catherine McCulleySioux Falls$5K
- Heather MitzelSioux Falls$5K
- Tiffanie VaneimerenSioux Falls$4K
- Sara NewmanSioux Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.